Donation

The IMF’s Understanding series of cancer information booklets is designed to acquaint you with specific multiple myeloma-related tests, treatments and therapies, supportive care measures, and common adverse events.

 

Understanding a complex disease like myeloma can feel like you must learn a new language very quickly. The IMF’s signature publication,

Full of our informative publications, including our Patient Handbook and selections from the popular Understanding Series, the Info Pack will…

Immunotherapy with Abecma® (idecabtagene vicleucel or “ide-cel” for short) is FDA-approved for the treatment of relapsed refractory multiple myeloma…

Carvykti® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients…

This booklet serves as an introduction to cereblon E3 ligase modulatory drugs (CELMoDs), a new class of medications currently being studied in…
This publication discusses what myeloma patients should consider if enrolling in a clinical trial.
This publication discusses the use of DARZALEX (daratumumab) injection and DARZALEX FASPRO —for the treatment of myeloma.
This booklet discusses dexamethasone, a synthetic steroid that is one of the most frequently used medica­tions in the treatment of myeloma.
Elrexfio™ (elranatamab-bcmm) is a B-cell maturation antigen (BCMA)-directed CD3 T-cell engager.
This publication discusses the use of Empliciti (elotuzumab)—a monoclonal antibody—for the treatment of myeloma.
Patients with myeloma may experience fatigue caused by the disease itself or by treatment for myeloma, as well as by other medical problems or their…
This publication discusses the use of Kyprolis (carfilzomib)— a proteasome inhibitor—for the treatment of myeloma.
This publication covers monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
The International Myeloma Foundation provides this glossary that defines commonly used multiple myeloma-related terms
This publication discusses peripheral neuropathy, which can be a complication of multiple myeloma or its treatments.
This publication discusses the use of Ninlaro (ixazomib)—a proteasome inhibitor—for the treatment of myeloma.
This publication discusses the use of Pomalyst (pomalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
This publication discusses the use of Revlimid (lenalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and…
This publication is for myeloma patients in the U.S. who are considering undergoing an autologous stem cell transplant (ASCT).
Talvey is indicated for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy.
Tecvayli™ (teclistamab-cqyv) is the first in a drug class of bispecific antibodies approved by the FDA to treat myeloma.
This publication discusses the use of Thalomid (Thalidomide)—an immunomodulatory drug (IMiD)—for the treatment of myeloma.
This publication discusses the effects of multiple myeloma on the immune system.
This booklet discusses Velcade (bortezomib), Revlimid (lenalidomide), and dexamethasone as treatment for newly diagnosed myeloma.
This publication focuses on therapies (such as bisphosphonates) given to patient with myeloma bone lesions, lytic lesions, or myeloma bone disease.
This publication discusses how myeloma patients can manage vertebral compression fractures.
This publication discusses the use of Velcade (bortezomib)—a proteasome inhibitor—for the treatment of myeloma.
This booklet discusses Xpovio (selinexor) for the treatment of multiple myeloma.
This booklet outlines the various tests that are used to diagnose and monitor myeloma, and to detect response and relapse.

with support from:

Johnson & Johnson, Sanofi, and Pfizer.

Give Where Most Needed